Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BNT 211

Drug Profile

BNT 211

Alternative Names: Anti-claudin 6 CAR T-cell therapy - BioNTech; Anti-claudin 6 chimeric antigen receptor cell therapy - BioNTech; Anti-CLDN6 chimeric antigen receptor cell therapy - BioNTech; BNT-211; CLDN6 CAR-T therapy - BioNTech

Latest Information Update: 24 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 16 Sep 2020 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (IV, Infusion) (NCT04503278)
  • 30 Jun 2020 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in Germany (IV, Infusion) (EudraCT2019-004323-20)
  • 12 May 2020 BioNTech plans a phase I/II trial for Solid tumours (Late stage disease) in the second half of 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top